JP Morgan Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Rachel Vatnsdal maintains an Overweight rating on Adaptive Biotechnologies (NASDAQ:ADPT) and raises the price target from $5 to $6.
August 02, 2024 | 8:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Rachel Vatnsdal maintains an Overweight rating on Adaptive Biotechnologies and raises the price target from $5 to $6.
The Overweight rating and increased price target from a reputable analyst at JP Morgan is likely to boost investor confidence and positively impact the stock price of Adaptive Biotechnologies in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100